Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Last year saw the highest private in-patient admissions since records began, totaling roughly 900,000, a 7% increase from 2022.
Beijing is reportedly unhappy with the prospect of an EU tariff on EVs, and is considering retaliatory tariffs on the EU’s aviation industry.
The industry just boosted its profit forecast for 2024 but warns that return on invested capital hurts the chance for sustainable profits.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
The brewer is reportedly in early talks to sell to Japan’s Suntory, which owns American spirits brands Jim Beam and Maker’s Mark.
The big services are working on a structure that will weigh factors such as viewership time, production budget, and new subscriptions added.
Once thought to be fizzling, fizzy drinks are bubbling with growth and investment at a pace not seen in years.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
As juice-sucking tech firms battle for artificial intelligence supremacy, the coal industry has been cleaning up.
The deal provides increased operations both outside of and within the highly desirably Permian Basin oil fields of Western Texas.
The drug-store chain lowered prices on more than 1,500 items including vitamins, chips, lotion, and Squishmallow plushies.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.